These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
315 related articles for article (PubMed ID: 25586068)
21. Improvements in both psychosis and motor signs in Parkinson's disease, and changes in regional cerebral blood flow after electroconvulsive therapy. Usui C; Hatta K; Doi N; Kubo S; Kamigaichi R; Nakanishi A; Nakamura H; Hattori N; Arai H Prog Neuropsychopharmacol Biol Psychiatry; 2011 Aug; 35(7):1704-8. PubMed ID: 21605615 [TBL] [Abstract][Full Text] [Related]
22. Psychotic and depressive symptoms in Parkinson's disease. A study of the growth hormone response to apomorphine. Mellers JD; Quinn NP; Ron MA Br J Psychiatry; 1995 Oct; 167(4):522-6. PubMed ID: 8829723 [TBL] [Abstract][Full Text] [Related]
23. Psychotic symptoms in Parkinson's disease. From description to etiology. Papapetropoulos S; Mash DC J Neurol; 2005 Jul; 252(7):753-64. PubMed ID: 15999234 [TBL] [Abstract][Full Text] [Related]
24. Course, prognosis, and management of psychosis in Parkinson's disease: are current treatments really effective? Zahodne LB; Fernandez HH CNS Spectr; 2008 Mar; 13(3 Suppl 4):26-33. PubMed ID: 18323764 [TBL] [Abstract][Full Text] [Related]
25. [Dopaminomimetic psychosis in Parkinson's disease: first symptom of early dementia?]. Catalan-Alonso MJ; Del Val J Rev Neurol; 2001 Jun 1-15; 32(11):1085-7. PubMed ID: 11562835 [TBL] [Abstract][Full Text] [Related]
27. Quetiapine improves psychotic symptoms and cognition in Parkinson's disease. Juncos JL; Roberts VJ; Evatt ML; Jewart RD; Wood CD; Potter LS; Jou HC; Yeung PP Mov Disord; 2004 Jan; 19(1):29-35. PubMed ID: 14743357 [TBL] [Abstract][Full Text] [Related]
28. [Clozapine and olanzapine in the treatment of the psychotic disorders in Parkinson's disease]. Chacón J Rev Neurol; 2004 Oct 1-15; 39(7):655-60. PubMed ID: 15490354 [TBL] [Abstract][Full Text] [Related]
29. Genetic polymorphism of the angiotensin converting enzyme and L-dopa-induced adverse effects in Parkinson's disease. Lin JJ; Yueh KC; Lin SZ; Harn HJ; Liu JT J Neurol Sci; 2007 Jan; 252(2):130-4. PubMed ID: 17196621 [TBL] [Abstract][Full Text] [Related]
33. Development and evaluation of the Parkinson Psychosis Questionnaire A screening-instrument for the early diagnosis of drug-induced psychosis in Parkinson's disease. Brandstaedter D; Spieker S; Ulm G; Siebert U; Eichhorn TE; Krieg JC; Oertel WH; Eggert K J Neurol; 2005 Sep; 252(9):1060-6. PubMed ID: 15789127 [TBL] [Abstract][Full Text] [Related]
34. Compulsive behaviors in patients with Parkinson's disease. Kenangil G; Ozekmekçi S; Sohtaoglu M; Erginöz E Neurologist; 2010 May; 16(3):192-5. PubMed ID: 20445429 [TBL] [Abstract][Full Text] [Related]
35. [Levodopa dependency in Parkinson's disease: case report and review]. Müller U; Reuter M; Hermann W; Gertz HJ Nervenarzt; 2002 Sep; 73(9):887-91. PubMed ID: 12215883 [TBL] [Abstract][Full Text] [Related]
36. Clozapine in the treatment of psychosis in Parkinson's disease. Friedman JH; Lannon MC Neurology; 1989 Sep; 39(9):1219-21. PubMed ID: 2771073 [TBL] [Abstract][Full Text] [Related]
37. Features associated with the development of hallucinations in Parkinson's disease. Benbir G; Ozekmekçi S; Cinar M; Beskardes F; Apaydin H; Erginöz E Acta Neurol Scand; 2006 Oct; 114(4):239-43. PubMed ID: 16942542 [TBL] [Abstract][Full Text] [Related]